ResMed (FRA:RMEA) 3-Year EPS without NRI Growth Rate : 14.70% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is ResMed 3-Year EPS without NRI Growth Rate?

ResMed's EPS without NRI for the three months ended in Dec. 2023 was €0.17.

During the past 12 months, ResMed's average EPS without NRI Growth Rate was 13.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 14.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of ResMed was 84.40% per year. The lowest was -2.40% per year. And the median was 21.60% per year.

Competitive Comparison of ResMed's 3-Year EPS without NRI Growth Rate

For the Medical Instruments & Supplies subindustry, ResMed's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ResMed's 3-Year EPS without NRI Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where ResMed's 3-Year EPS without NRI Growth Rate falls into.

ResMed 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

ResMed (FRA:RMEA) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

ResMed 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of ResMed's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

ResMed (FRA:RMEA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (FRA:RMEA) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMD:USA RMD:Mexico R1MD34:Brazil RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed (FRA:RMEA) Headlines

No Headlines